Pfizer Inc. PFE
Set alert
At close · Oct 30
After hours · Oct 30, 7:55 PM ET
- YTD
- +22.57%
- 1 year
- +25.65%
- Open
- 30.51
- Prev close
- 29.95
- Mkt cap
- 173.95B
- Vol
- 45.49M
- Avg vol
- 33.75M
- EPS
- 0.76
- P/E
- 40.16
- Div yield
- 5.74%
More statistics
- Low
- 30.14
- High
- 30.65
- Forward P/E
- 10.58
- Beta
- 0.28
- Short ratio
- 4.20
- Inst. own
- 69.06%
- Dividend
- 1.72
- Ex-div date
- Nov 5, 2026
- Earnings
- Nov 3, 2026
- 50-d avg
- 28.49
- 200-d avg
- 26.77
- 1y target
- 29.26
5D chart
Signals (88)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 3:50 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:45 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:40 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:30 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:30 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:15 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:30 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 12:55 PM | 1 day ago |
| RSI: Overbought | Oct 30, 12:40 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 12:20 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:05 PM | 1 day ago |
| SMA: Bearish | Oct 30, 11:45 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:50 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 10:20 AM | 1 day ago |
| RSI: Overbought | Oct 30, 10:10 AM | 1 day ago |
| SMA: Bearish | Oct 30, 10:05 AM | 1 day ago |
| RSI: Overbought | Oct 29, 3:15 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:15 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:50 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 28, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:15 PM | 3 days ago |
| RSI: Oversold | Oct 28, 1:15 PM | 3 days ago |
| RSI: Oversold | Oct 28, 12:15 PM | 3 days ago |
| RSI: Oversold | Oct 28, 12:00 PM | 3 days ago |
| SMA: Bearish | Oct 28, 11:00 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:00 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:00 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:55 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:55 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:10 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 9:50 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 3 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 27, 3:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:15 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:40 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:20 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 4 days ago |
| RSI: Oversold | Oct 27, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:15 PM | 5 days ago |
| RSI: Oversold | Oct 26, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 11:50 AM | 5 days ago |
| RSI: Oversold | Oct 26, 11:20 AM | 5 days ago |
| RSI: Oversold | Oct 26, 11:05 AM | 5 days ago |
News
1 day ago fool.com
Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real?
Pfizer shares are up amid bullish sentiment about the pharmaceutical company's turnaround efforts. The upcoming loss of patent exclusivity for several blockbuster drugs could prevent a full recovery…
1 day ago 247wallst.com
$250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends
Dividends keep paying whether you sell or not, and four healthcare giants quietly generate serious retirement income while you sleep. But not every yield here is as safe as it looks.
1 day ago 247wallst.com
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
A strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a standout healthcare gainer on a day when tech stocks are selling off. In morning trading, Regeneron…
1 day ago seekingalpha.com
Pfizer: Reality Check Ahead Of Earnings
Pfizer is downgraded from 'Buy' to 'Hold' as analyst sentiment turns increasingly bearish and growth prospects dim. Consensus expects declining revenue and EPS through 2029, with skepticism about…
2 days ago 247wallst.com
Pfizer Yields Nearly 6%, but Its Dividend Exceeds Free Cash Flow. Is It Safe?
Pfizer's dividend yield sits near 6%, but the company paid out more in dividends last year than it generated in free cash flow.
2 days ago zacks.com
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?
GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
2 days ago businesswire.com
Edison Scientific Announces Agreement with Pfizer to Accelerate Research and Development
SAN FRANCISCO--(BUSINESS WIRE)--Edison Scientific announces agreement with Pfizer to accelerate research and development.
2 days ago zacks.com
Exploring Analyst Estimates for Pfizer (PFE) Q3 Earnings, Beyond Revenue and EPS
Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for…
2 days ago 247wallst.com
Are Your Dividends Safe? 4 Yields That Are High for the Wrong Reason
Some of the fattest dividend yields on the market right now come from stocks that have already cut their payouts once, and three more may be quietly building toward the same moment. Here is what the…
3 days ago 247wallst.com
Obesity Pipeline vs. COVID Drag: The Hidden Numbers Deciding Pfizer's Q3 Fate on Nov. 3
Pfizer (NYSE:PFE | PFE Price Prediction) reports third-quarter results before the open on Tuesday, Nov. 3. Shares have gained 25% year to date.
3 days ago zacks.com
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
Pfizer (PFE) closed at $29.45 in the latest trading session, marking a -1.17% move from the prior day.
3 days ago zacks.com
Pfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy?
Pfizer heads into Q3 earnings with strong drug sales and an attractive valuation, but declining COVID revenues and looming patent expirations pose challenges.
4 days ago fool.com
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now
The stocks listed here yield up to 5.8%.
4 days ago benzinga.com
Pfizer Cancer Therapy Shows Extended Progression-Free Survival in Multiple Myeloma Patients
Pfizer Inc. (NYSE:PFE) on Tuesday released topline results from its Phase 3 MagnetisMM-32 study evaluating Elrexfio (elranatamab) as a monotherapy.
4 days ago benzinga.com
Pfizer Cancer Therapy Shows Extended Progression-Free Survival in Multiple Myeloma Patients
Pfizer reports positive Phase 3 ELREXFIO data showing reduced disease progression risk in relapsed or refractory multiple myeloma patients.
4 days ago 247wallst.com
$200,000 in Dividend Stocks: How Much More Could You Keep in a Roth IRA?
Parking six popular dividend stocks in a taxable account quietly hands the IRS a cut of every payout, and one holding in your portfolio is almost certainly the biggest culprit.
4 days ago zacks.com
Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 days ago fool.com
3 Dirt Cheap Dividend Stocks to Buy Hand Over Fist
These three high-yield dividend stocks could surge once investors realize they've overreacted to recent headwinds.
-
5 days ago benzinga.com
Pfizer Announces That Topline Results In The Phase 3 MagnetisMM-32 Trial Of ELREXFIO Demonstrated Clinically Meaningful And Statistically Significant Benefit For Patients Whose Disease Progressed After Anti-CD38 Therapy And Lenalidomide, With Median PFS Not Yet Reached
Pfizer Inc. (NYSE:PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma…
5 days ago businesswire.com
Pfizer's ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or…
5 days ago gurufocus.com
Pfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
[url="]Pfizer Inc. (NYSE: PFE)[/url] today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNAÂ (talazoparib) in combi
5 days ago businesswire.com
Pfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNA® (talazoparib) in combination with XTANDI®…
5 days ago 247wallst.com
How Much Retirement Income Could $100,000 in These 3 Dividend Stocks Generate?
Three companies in pharmaceuticals, energy, and tobacco operate in entirely different worlds, and that separation is exactly the point for retirees who need their income to survive whatever the…
5 days ago 247wallst.com
Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an earlier study suggested in a late-stage trial.
-
6 days ago benzinga.com
Reported Saturday, Pfizer Presents Phase 2 25vPnC Infant Data At IDWeek 2026: Robust Responses To All 25 Serotypes, Including Five New, Safety Comparable To PREVNAR 20, No Related Serious Adverse Events
Investigational vaccine shows strong immune responses in infants equivalent to PREVNAR 20 on shared serotypes and for five new serotypes, potentially offering the broadest protection against invasive…
6 days ago seekingalpha.com
Buy 8 Barron's Big Better Bets (Than T-Bills) Out Of 14 'Safer' October DiviDogs
Eight of the fourteen highest-yield 'Safer' Big BBB Dogs, including Suburban Propane, Verizon, and Realty Income, currently meet the dogcatcher ideal for buyable dividend value. Analyst 1-year…
1 week ago benzinga.com
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Analysts highlight high-yield healthcare stocks Perrigo (7.09%), Pfizer (5.65%) and CVS Health (2.82%), with updated ratings and news.
1 week ago benzinga.com
Swiss Pharma Giant Roche Suspends German Capital Commitments Amid Dispute Over Drug Discounts
Roche halts German investments as chief Daniel Steiners warns Berlin that statutory drug rebates shatter trust in the market.
2 weeks ago benzinga.com
JD Vance Touts TrumpRx Drug Price Push, Trump Accounts as ‘Economic Nationalism’ Wins Ahead Of Midterms
JD Vance touted TrumpRx and Trump Accounts as key economic wins, highlighting prescription drug savings ahead of the midterm elections.
2 weeks ago benzinga.com
Pfizer Stock Hits 52-Week High: What's Going On?
Pfizer Inc (NYSE:PFE) shares are climbing Thursday to a new 52-week high as drugmakers rally broadly. The move comes a week after the FDA approved a Tukysa regimen.
2 weeks ago benzinga.com
Pfizer, Thermo Fisher Scientific And More: CNBC’s ‘Final Trades’
CNBC Final Trades: Weiss picked 10-year Treasuries, Thomas chose XAR, Firestone favored TMO, and Terranova selected PFE.
2 weeks ago benzinga.com
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.
-
3 weeks ago benzinga.com
JP Morgan Maintains Neutral on Pfizer, Raises Price Target to $30
JP Morgan analyst Chris Schott maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $28 to $30.
3 weeks ago benzinga.com
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRNA, BNTX, and NVAX surging Friday.
-
3 weeks ago benzinga.com
Cantor Fitzgerald Maintains Neutral on Pfizer, Raises Price Target to $28
Cantor Fitzgerald analyst Carter Gould maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $27 to $28.
3 weeks ago benzinga.com
Pharma Lobby Sues Trump Administration Over Medicare Drug Pricing Rule, Calls It ‘Unlawful Overreach’ — ‘The Results Are Preordained’
PhRMA sued the Trump administration over its Medicare drug pricing rule, arguing CMS exceeded its authority under federal law.
3 weeks ago benzinga.com
Pfizer Expands Breast Cancer Drug Reach with New FDA Nod for Metastatic Disease
The FDA approved Pfizer's TUKYSA combination as a front-line maintenance therapy for advanced HER2-positive breast cancer.
-
3 weeks ago benzinga.com
Pfizer’s TUKYSA Regimen Obtains FDA Approval As Front-Line Maintenance Treatment For HER2+ Metastatic Breast Cancer
TUKYSA in combination with trastuzumab and pertuzumab showed more than 50% improvement in median progression-free survival, supporting approval as a chemotherapy-free maintenance optionPfizer Inc.…
3 weeks ago benzinga.com
Florida Attorney General Sues Pfizer for 'Misleading' COVID-19 Vaccine Safety Claims
Florida files a lawsuit against Pfizer and CEO Albert Bourla over alleged deceptive vaccine marketing and undisclosed health risks.
3 weeks ago benzinga.com
Vaxcyte Stock Hits New 52-Week High - Here’s Why
Vaxcyte announced positive Phase 3 OPUS-1 trial results for its VAX-31 vaccine candidate, setting the stage for an FDA BLA filing.
-
4 weeks ago benzinga.com
Pfizer Announces Its Two Phase 3 Studies Of LITFULO Demonstrate TRANQUILLO 2 and TRANQUILLO, LITFULO Enhance Facial, Total Body Repigmentation Compared To Placebo; Co. Plans To File Data to Regulatory Authorities Globally, Include FDA And European Medicines Agency
Pfizer Inc. (NYSE:PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a wide range of disease…
1 month ago benzinga.com
Pfizer Says Eczema Drug Shows Significant Skin Clearance
Pfizer reports positive Phase 2 trial results for tilrekimig in treating moderate-to-severe atopic dermatitis at the EADV Congress.
1 month ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago benzinga.com
Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody
Invivyd reported Phase 3 LIBERTY trial data for VYD2311, showing strong safety and enhanced COVID-19 antibody levels.
-
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago benzinga.com
Full Transcript: Pfizer Q2 2026 Earnings Call
Pfizer (NYSE:PFE) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call…
1 month ago benzinga.com
Trump's Drug Price Achievements Questioned Following Separate Most Favored Nation Contract Disclosures with Lilly, Pfizer
Public Citizen exposes separate government drug deals with Pfizer and Eli Lilly, warning the pacts could increase global drug prices.
1 month ago benzinga.com
Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer
European committee backs Merck's Keytruda + Padcev combo for bladder cancer after Phase 3 trial slashes risk of recurrence by 47%.
1 month ago benzinga.com
Trump's Surgeon General Pick Has Tobacco, Cola Stocks In Portfolio Even as Robert Kennedy Jr. Wages War On Sugary Drinks, Processed Food
President Trump's Surgeon General nominee Dr. Nicole Saphier disclosed investments in Philip Morris and other companies, agreeing to divest if confirmed.
1 month ago benzinga.com
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Medicus Pharma partners with Pfizer to commercialize CD228V in a licensing deal worth over $1 billion plus royalties.